InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a research note issued on Saturday. The firm set a “sell” rating on the stock.

InspireMD Stock Performance

NSPR opened at $2.59 on Friday. The company has a market capitalization of $76.90 million, a P/E ratio of -3.45 and a beta of 0.74. The company has a 50-day moving average of $2.83 and a 200-day moving average of $2.74. InspireMD has a 1-year low of $1.81 and a 1-year high of $3.80.

Hedge Funds Weigh In On InspireMD

Several hedge funds and other institutional investors have recently modified their holdings of NSPR. Parkman Healthcare Partners LLC increased its position in InspireMD by 721.2% in the 4th quarter. Parkman Healthcare Partners LLC now owns 854,716 shares of the company’s stock valued at $2,248,000 after acquiring an additional 750,635 shares during the period. Affiance Financial LLC grew its stake in shares of InspireMD by 2.9% in the fourth quarter. Affiance Financial LLC now owns 189,122 shares of the company’s stock worth $497,000 after purchasing an additional 5,376 shares in the last quarter. Essex Investment Management Co. LLC acquired a new position in shares of InspireMD during the fourth quarter valued at $191,000. Northern Trust Corp raised its stake in shares of InspireMD by 103.7% during the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock valued at $126,000 after purchasing an additional 24,452 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC lifted its holdings in InspireMD by 153.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock worth $79,000 after purchasing an additional 18,233 shares during the period. Institutional investors and hedge funds own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.